Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsPitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Advances in neuro-oncology imaging.Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Histogram Analysis of Diffusion Tensor Imaging Parameters in Pediatric Cerebellar Tumors.Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade.Diffusion Weighted/Tensor Imaging, Functional MRI and Perfusion Weighted Imaging in Glioblastoma-Foundations and Future.Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.Imaging in neuro-oncology.Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomasUse of Apparent Diffusion Coefficient Histogram in Differentiating Between Medulloblastoma and Pilocytic Astrocytoma in Children
P2860
Q26853308-20F2A73A-8283-4324-A388-647F86ED07A1Q30907831-3EF8925D-6FDC-4EF5-873E-C22734D159B5Q35771783-CFFAE72F-98F4-4785-8145-CE329F9A4335Q36339461-A362F37F-C6EC-41AD-AAD5-4B1EF4E594D3Q36427409-4481F509-D07E-43D3-AFC7-5C289D351EC6Q37510450-47AA5439-EC6A-4C69-A07B-4D6BE687937CQ38789124-F484E039-0B2F-4269-96A5-F03FBD591406Q39312420-0A7243ED-4A23-483E-9E1C-F5A0EC2F68AEQ40583093-02344454-2759-4542-97FB-B126EB5D6D1FQ40721144-C7CDB960-58F1-423C-95B5-C2C067507D6EQ41462863-5E38D339-A749-4725-BB47-1DEC4DE469E7Q42702318-8317BE48-7711-4FE7-A62A-C0306AE0B2D9Q47208201-FCB91E22-8F13-42F5-9C5F-D0EC664DE9A9Q49274965-ABE635F2-C3BE-48EE-AA5C-E304AF827693Q49499240-505A79D4-2778-4112-A222-82C36404A097Q54973707-CAA92AE3-7F47-42A7-B607-0ADFAEF8A552Q55035317-72169EFA-54BB-4EE4-B94A-773E75ED7527Q57177114-88C84CF7-1300-4FCB-AFD0-37EA25B15EA2Q58770296-20FA54A7-FD3B-41AF-A11F-DCDFA3AE8139
P2860
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Histogram analysis of apparent ...... ents treated with bevacizumab.
@en
Histogram analysis of apparent ...... ents treated with bevacizumab.
@nl
type
label
Histogram analysis of apparent ...... ents treated with bevacizumab.
@en
Histogram analysis of apparent ...... ents treated with bevacizumab.
@nl
prefLabel
Histogram analysis of apparent ...... ents treated with bevacizumab.
@en
Histogram analysis of apparent ...... ents treated with bevacizumab.
@nl
P2093
P2860
P1476
Histogram analysis of apparent ...... ents treated with bevacizumab.
@en
P2093
Alhafidz Hamdan
Andrew D Norden
Patrick Y Wen
Raymond Y Huang
Rebecca Zweifler
Rifaquat Rahman
Srinivasan Mukundan
P2860
P2888
P304
P356
10.1007/S11060-014-1464-8
P577
2014-05-08T00:00:00Z